384 related articles for article (PubMed ID: 18387931)
1. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
Nissen SE; Nicholls SJ; Wolski K; Rodés-Cabau J; Cannon CP; Deanfield JE; Després JP; Kastelein JJ; Steinhubl SR; Kapadia S; Yasin M; Ruzyllo W; Gaudin C; Job B; Hu B; Bhatt DL; Lincoff AM; Tuzcu EM;
JAMA; 2008 Apr; 299(13):1547-60. PubMed ID: 18387931
[TBL] [Abstract][Full Text] [Related]
2. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
[TBL] [Abstract][Full Text] [Related]
3. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
[TBL] [Abstract][Full Text] [Related]
4. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial.
O'Leary DH; Reuwer AQ; Nissen SE; Després JP; Deanfield JE; Brown MW; Zhou R; Zabbatino SM; Job B; Kastelein JJ; Visseren FL;
Heart; 2011 Jul; 97(14):1143-50. PubMed ID: 21610270
[TBL] [Abstract][Full Text] [Related]
5. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
Nissen SE; Nicholls SJ; Sipahi I; Libby P; Raichlen JS; Ballantyne CM; Davignon J; Erbel R; Fruchart JC; Tardif JC; Schoenhagen P; Crowe T; Cain V; Wolski K; Goormastic M; Tuzcu EM;
JAMA; 2006 Apr; 295(13):1556-65. PubMed ID: 16533939
[TBL] [Abstract][Full Text] [Related]
6. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Nissen SE; Nicholls SJ; Wolski K; Nesto R; Kupfer S; Perez A; Jure H; De Larochellière R; Staniloae CS; Mavromatis K; Saw J; Hu B; Lincoff AM; Tuzcu EM;
JAMA; 2008 Apr; 299(13):1561-73. PubMed ID: 18378631
[TBL] [Abstract][Full Text] [Related]
7. Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial.
Nicholls SJ; Puri R; Ballantyne CM; Jukema JW; Kastelein JJP; Koenig W; Wright RS; Kallend D; Wijngaard P; Borgman M; Wolski K; Nissen SE
JAMA Cardiol; 2018 Sep; 3(9):806-814. PubMed ID: 30046837
[TBL] [Abstract][Full Text] [Related]
8. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial.
Nicholls SJ; Bakris GL; Kastelein JJ; Menon V; Williams B; Armbrecht J; Brunel P; Nicolaides M; Hsu A; Hu B; Fang H; Puri R; Uno K; Kataoka Y; Bash D; Nissen SE
JAMA; 2013 Sep; 310(11):1135-44. PubMed ID: 23999933
[TBL] [Abstract][Full Text] [Related]
9. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
Hollander P
Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
[TBL] [Abstract][Full Text] [Related]
10. Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial.
Nicholls SJ; Andrews J; Kastelein JJP; Merkely B; Nissen SE; Ray KK; Schwartz GG; Worthley SG; Keyserling C; Dasseux JL; Griffith L; Kim SW; Janssan A; Di Giovanni G; Pisaniello AD; Scherer DJ; Psaltis PJ; Butters J
JAMA Cardiol; 2018 Sep; 3(9):815-822. PubMed ID: 30046828
[TBL] [Abstract][Full Text] [Related]
11. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
[TBL] [Abstract][Full Text] [Related]
12. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
[TBL] [Abstract][Full Text] [Related]
14. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Christopoulou FD; Kiortsis DN
J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
[TBL] [Abstract][Full Text] [Related]
15. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP; Golay A; Sjöström L;
N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
[TBL] [Abstract][Full Text] [Related]
16. Rimonabant and progression of atherosclerosis in obese persons.
Dora JM; Scheffel RS
JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538
[No Abstract] [Full Text] [Related]
17. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Després JP; Ross R; Boka G; Alméras N; Lemieux I;
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain.
Rigotti NA; Gonzales D; Dale LC; Lawrence D; Chang Y;
Addiction; 2009 Feb; 104(2):266-76. PubMed ID: 19149823
[TBL] [Abstract][Full Text] [Related]
19. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.
Hirohata A; Yamamoto K; Miyoshi T; Hatanaka K; Hirohata S; Yamawaki H; Komatsubara I; Murakami M; Hirose E; Sato S; Ohkawa K; Ishizawa M; Yamaji H; Kawamura H; Kusachi S; Murakami T; Hina K; Ohe T
J Am Coll Cardiol; 2010 Mar; 55(10):976-82. PubMed ID: 20202514
[TBL] [Abstract][Full Text] [Related]
20. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
